MHLW Designates Alexion’s Eculizumab Orphan Drug
This article was originally published in PharmAsia News
Executive Summary
The first section on drugs at the Pharmaceutical Affairs and Food Sanitation council designated eculizumab, a paroxysmal nocturnal hemoglobinuria drug manufactured and marketed by Alexion Pharmaceuticals. There are an estimated 430 PNH patients in Japan. (Click here for more - Japanese language